0001209191-23-019885.txt : 20230317
0001209191-23-019885.hdr.sgml : 20230317
20230317182223
ACCESSION NUMBER: 0001209191-23-019885
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230315
FILED AS OF DATE: 20230317
DATE AS OF CHANGE: 20230317
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Holdbrook Mark J.
CENTRAL INDEX KEY: 0001827564
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39614
FILM NUMBER: 23744302
MAIL ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD, SUITE 160
CITY: IRVINE
STATE: CA
ZIP: 92618
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001819790
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 814717861
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
BUSINESS PHONE: (949) 409-9820
MAIL ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-15
0
0001819790
Tarsus Pharmaceuticals, Inc.
TARS
0001827564
Holdbrook Mark J.
C/O TARSUS PHARMACEUTICALS, INC.
15440 LAGUNA CANYON ROAD, SUITE 160
IRVINE
CA
92618
0
1
0
0
V.P., Clinical Affairs
Common Stock
2023-03-15
4
M
0
2653
A
3764
D
Common Stock
2023-03-16
4
S
0
187
13.43
D
3577
D
Restricted Stock Units
2023-03-15
4
M
0
2653
0.00
D
Common Stock
2653
7959
D
The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
Includes 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022.
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Each RSU represents a contingent right to receive one share of the Company's common stock.
RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.
/s/ Leonard M. Greenstein, Attorney-in-Fact
2023-03-17